CN113662857A - Medicine storage system and method - Google Patents
Medicine storage system and method Download PDFInfo
- Publication number
- CN113662857A CN113662857A CN202110986251.1A CN202110986251A CN113662857A CN 113662857 A CN113662857 A CN 113662857A CN 202110986251 A CN202110986251 A CN 202110986251A CN 113662857 A CN113662857 A CN 113662857A
- Authority
- CN
- China
- Prior art keywords
- medicine
- storage system
- taking
- composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 356
- 229940079593 drug Drugs 0.000 title claims abstract description 76
- 238000003860 storage Methods 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 208000030963 borderline personality disease Diseases 0.000 claims abstract description 38
- 230000008569 process Effects 0.000 claims description 25
- 230000037406 food intake Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000000857 drug effect Effects 0.000 claims description 3
- 230000036962 time dependent Effects 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000010219 correlation analysis Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 239000000284 extract Substances 0.000 description 74
- 229960004170 clozapine Drugs 0.000 description 35
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 35
- 230000006399 behavior Effects 0.000 description 32
- 238000012544 monitoring process Methods 0.000 description 21
- 230000009471 action Effects 0.000 description 17
- 239000006187 pill Substances 0.000 description 17
- 238000007789 sealing Methods 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 208000022821 personality disease Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000006838 adverse reaction Effects 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 229930002966 sinomenine Natural products 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 230000008451 emotion Effects 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 4
- 235000007516 Chrysanthemum Nutrition 0.000 description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036630 mental development Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000027288 circadian rhythm Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 210000004916 vomit Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000010681 turmeric oil Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019509 white turmeric Nutrition 0.000 description 2
- 241000427159 Achyranthes Species 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 240000008537 Burchellia bubalina Species 0.000 description 1
- 235000004415 Burchellia bubalina Nutrition 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009001 hormonal pathway Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0481—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers working on a schedule basis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0418—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0427—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system
- A61J7/0436—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system resulting from removing a drug from, or opening, a container
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/30—Compliance analysis for taking medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/70—Device provided with specific sensor or indicating means
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug storage system and method, comprising a drug for treating borderline personality disorder and a storage device for storing the drug. The medicament for borderline personality disorder consists of the following two compositions: the time constitutes the first composition of the critical condition for taking and the dosage constitutes the second composition of the critical condition for taking.
Description
Technical Field
The invention relates to the field of medical machinery, in particular to a medicine storage system and a medicine storage method.
Background
Mood Disorder of unstable Personality is also known as Borderline Personality Disorder (BPD). Borderline personality disorder is a common personality disorder in the psychiatric department, is mainly characterized by instability of emotion, interpersonal relationship, self-image and behavior and is accompanied by various impulsive behaviors, and is a complex and serious mental disorder. Borderline personality disorder is typically characterized by "stable instability" described by scholars, often manifested by non-compliance with treatment and great difficulty in treatment. Clinical patients may present with anxiety, depression, fear, and also "hypersensitivity hallucinations" and "hypersensitivity-related delusions". In the traditional Chinese medicine field, borderline personality disorder is mostly 'depressive psychosis' and 'mania'. The traditional Chinese medicine considers that the occurrence of borderline personality disorder is closely related to 'blood storage' and 'qi and blood stagnation' so that the brain qi is not connected with the qi of viscera to form the borderline personality disorder. Clozapine, as a representative of Second-Generation Antipsychotics (SGAs), has a good auxiliary effect on borderline personality disorder, can directly inhibit the brain stem network ascending activation system, and has a strong sedative and hypnotic effect. During the administration of clozapine, the neurotransmitter blocking effect causes other antagonisms of the body system during the sedation or hypnosis process of the human body, thereby causing side effects such as headache and vomit during the sedation or after the sedation. Therefore, more researchers are looking at traditional medicine today. The therapeutic concept of traditional medicine is becoming accepted worldwide. In the aspect of psychiatric department, more and more researchers adopt the combination of traditional Chinese medicine and western medicine to treat marginal personality disorder, and obtain better curative effect.
Chinese patent with publication number CN105031513A discloses a Chinese medicine for treating borderline personality disorder, which is prepared by the following Chinese medicines in parts by mass: 10 parts of uncaria, 10 parts of white paeony root, 3 parts of buffalo horn, 10 parts of tree peony bark, 15 parts of abalone shell, 10 parts of radix rehmanniae, 10 parts of pinellia tuber, 10 parts of arisaema cum bile, 10 parts of baical skullcap root, 10 parts of grassleaf sweelflag rhizome, 10 parts of turmeric root-tuber, 10 parts of twotooth achyranthes root, 10 parts of tabasheer, 10 parts of barbary wolfberry fruit, 8 parts of chrysanthemum, 10 parts of common macrocarpium fruit and 7 parts of liquoric root. The composition is prepared by medicines according to the traditional Chinese medicine principle of six meridians of human body to relieve or treat marginal personality disorder, but the effect is proved by experiments. Further, based on certain abnormalities of borderline personality disorder and schizophrenia in the neurotransmitter direction, the chinese patent with publication number CN106237268B discloses a pharmaceutical composition for treating schizophrenia, adverse reactions refer to constipation, dry mouth and weight gain, and the pharmaceutical composition is composed of the following raw material medicines: 2.5ml of zedoary turmeric oil, 1000g of red paeony root, 1000g of raw rhubarb and risperidone; 2.5ml of zedoary turmeric oil, 1000g of red peony root and 1000g of raw rhubarb are made into 1000 pieces of nutrient-regulating tablet, 8-10 pieces each time, 3 times a day; the risperidone dosage is increased from 1mg/d to 2-4mg/d within 1 week. The composition takes risperidone as a nerve blocking agent, and is supplemented with traditional Chinese medicine components to relieve adverse reactions generated in the nerve blocking process. For the side effect of nerve block, the side effect is caused by the conflict between the psychology and other hormone regulation paths of the body after the patient takes the medicine and the recognition of abnormal neurotransmitter, therefore, the traditional Chinese medicine composition for the adverse reaction can be designed from the direction of regulating the abnormal hormone secretion of the human body, thereby relieving the adverse reaction from the root. Due to the fact that the properties of medicinal materials and the physical characteristics of human bodies in different seasons are different, when the medicinal materials are taken in cooperation, the medicine property can be activated to the maximum degree, the body can reach the optimal medicine matching degree, the spleen and stomach theory written in Lidongyuan is explained, and the effect that the people are in good condition and do not live in peace in the heaven is achieved. And (2) the following: when there is no violation, there is no felling. And (2) the following: without the generation of varve gas. This is also true. "the literature indicates the importance of the time represented by solar terms or seasons for the progress of the drug administration. Based on the fact that patients with borderline personality disorder take medicines by themselves when being maintained outside the hospital with high mistaking rate and different traditional Chinese medicine taking components in different seasons, a device for the patients with borderline personality disorder to take medicines correctly needs to be configured for storing the medicine compositions taking the seasons as the intervals of taking medicines.
Furthermore, on the one hand, due to the differences in understanding to the person skilled in the art; on the other hand, since the inventor has studied a lot of documents and patents when making the present invention, but the space is not limited to the details and contents listed in the above, however, the present invention is by no means free of the features of the prior art, but the present invention has been provided with all the features of the prior art, and the applicant reserves the right to increase the related prior art in the background.
Disclosure of Invention
In view of the deficiencies of the prior art, the present invention contemplates a medication storage system comprising a medication for treating borderline personality disorder and a storage device for storing the medication. The medicine for borderline personality disorder consists of the following two compositions: the time constitutes the first composition of the critical condition for taking and the dosage constitutes the second composition of the critical condition for taking. Patients with borderline personality disorder lack self-management ability at least in a specific time period and cannot evaluate and predict self behaviors by themselves; its treatment depends not only on pharmacological measures but also on behavioral management. The personal emotional management disorder of such patient care personnel due to long-term care often constitutes a key problem in the care of such patients. While assisted treatment with "non-emotional, non-emotional feedback" smart devices has been a common technical measure, learning of such devices by patients and family members is of little interest and even presents extreme objections, and is therefore not widespread. In view of the above, the present invention focuses on the medicine taking measures that patients and caregivers must face, and adopts special equipment to train patients to form specific medicine taking behavior habits without being affected by 'emotional' fluctuation. By virtue of the taking training of the first and second compositions, in which the two types of drug effects are mutually promoted and the taking conditions constitute conditions with each other, the independent patients can be better treated and the behavioral characteristics are optimized. The two types of compositions which are restricted in time and have strict requirements on dosage are specially selected for the purpose, a compromise is found between complex and precise behavior treatment, and the composition can be accepted and used by most patients through extensive tests. Although the first and second compositions need to be administered with strict adherence to a specific time period for optimal drug treatment, the composition used in the present invention does not cause serious medical accidents if the patient can administer the second composition in an accurate dose without achieving the conditions between the two. Thus the first composition plays a more time-dependent role in the performance training or therapy, and furthermore the first composition of the invention, for example, employs a Chinese medicinal preparation familiar to older patients (such patients are most often elderly), so that the first composition is administered in a significantly different manner than the second composition (e.g. tablets), especially the first composition depends on a large number of manipulations and also requires significantly more liquid to drink, so that the image acquisition is sufficient to distinguish the behavior of the two. Therefore, the medicine storage system does not need a large amount of high-precision data analysis and behavior pattern recognition, does not need a complex and expensive biosensor, and is particularly suitable for families of mental patients with extremely high disease-causing poverty rate.
The prescribed dose of the second composition is provided by the medication storage system in a time-dependent manner, and the medication storage system stores and processes administration information in an image acquisition manner that is related to the time of provision of the second composition. The first composition includes at least four compositions whose times constitute key taking conditions and whose respective taking times are different from each other, wherein the prescribed taking time of each respective composition in the first composition is specified by the medication storage system in a manner correlated with the provision time of the second composition. The drug storage system stores and processes administration information of the respective components of the first composition in relation to the time of delivery of the second composition in an image capturing manner.
Preferably, the second composition can be clozapine. The first composition can be a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract comprises: the first traditional Chinese medicine extract, the second traditional Chinese medicine extract, the third traditional Chinese medicine extract and the fourth traditional Chinese medicine extract. The first traditional Chinese medicine extract is used for taking in spring and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 1-2 parts of lily and 5-10 parts of salvia miltiorrhiza. The second traditional Chinese medicine extract is taken in summer and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 15-30 parts of radix ophiopogonis, 5-15 parts of rosebush and 5-12 parts of chrysanthemum. The third traditional Chinese medicine extract is taken in autumn and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 55-105 parts of radix astragali and 10-20 parts of rhizoma gastrodiae. The fourth traditional Chinese medicine extract is used for taking in winter and comprises 5-10 parts of radix curcumae, 2-3 parts of agilawood, 5-10 parts of ginseng and 10-15 parts of rheum officinale. The time of the key medication conditions can be bounded by the time of day. The administration time in spring can be a time period from spring to beginning of summer. The administration time in summer can be a time period from summer to fall. The administration time in autumn can be a time interval from self-standing autumn to beginning winter. The administration time in winter can be a time interval from self-standing winter to spring.
The technical scheme has the advantages that: clozapine tablet for intracerebral 5-hydroxytryptamine (5-HT)2A) Receptor and Dopamine (DA)1) Has strong blocking effect on receptor, and can be used for treating Dopamine (DA)4) The receptor also has a blocking effect, can directly inhibit the brain stem network structure ascending activation system, and has strong sedative and hypnotic effects. Clozapine is able to achieve control of higher neural activity by inhibiting the transmission processes of the neural network. With the reduced neural activity of clozapine, other immune or hormonal pathways of the body can be based on countering abnormal neural activity and thus producing unpleasant physiological responses. Different from other psychotherapeutic drugs such as risperidone, clozapine can easily cause motor nerve spasm of tissues when being used for treating borderline personality disorder by blocking neurotransmitter movement, so that the problems of headache, strong stomach contraction and the like are caused, and adverse reactions such as vomit, headache and the like are caused. The traditional Chinese medicine composition is used for relieving the stress degree of a human body caused by qi and blood stasis stagnation when the clozapine is taken in the process of taking the medicine, so that the sensitivity of motor nerves and sensory nerves in each tissue is reduced, and the physiological reactions such as headache, vomiting and the like are inhibited. Furthermore, the active ingredients in the traditional Chinese medicine can be preserved to the maximum extent by using the traditional Chinese medicine composition in the form of the extract. The extract can achieve the process of slow release of the medicinal components in the absorption process, namely the action of the clozapineWhen the composition is used in the process of reaching the peak concentration of blood plasma within 3.2h, the Chinese medicinal composition in the extract can continuously keep the action on a human body with relatively stable medicament absorption rate, and adverse reactions such as vomiting, hiccup, adverse flow of qi, asthma, attack of wind-evil and the like caused by reduction of the nerve activity of the human body are relieved through pharmacological reaction on the human body. Because the traditional Chinese medicine has the particularity of priority of seasons in the processes of growth, picking and taking, particularly has different borderline personality disorder multiple syndromes in different seasons or seasons, the traditional Chinese medicine composition suitable for beginning spring, beginning summer, beginning autumn and beginning winter is adopted to relieve adverse reaction symptoms in the process of borderline personality disorder treatment. Note that mood-unstable personality disorder is also referred to as borderline personality disorder.
The medicine storage system judges the medicine taking sequence of a patient through image acquisition, and appoints the medicine taking sequence by selectively opening the sealing cover of the medicine box for storing clozapine or opening the sealing cover of the medicine box for storing traditional Chinese medicine extract. The first composition and the second composition of the medicine constituting the borderline personality disorder are stored in the medicine storage system without intersecting with each other, wherein the medicine storage system stores information related to the timing of taking of at least "the first composition constituting the key taking condition in time" and "the second composition constituting the key taking condition in dose" in an image-capturing manner, so that the timing of taking of the first composition and the second composition stored without intersecting with each other is stored in association with the taking behavior and the time correlation analysis can be performed.
According to a preferred embodiment, the drug storage system takes the first composition and the second composition chronologically after each other by alerting the patient and/or his care giver so that the respective patients take them for the purpose of enhancing the drug effects of each other. Preferably, the medicament for treating borderline personality disorder can comprise 0.5-2 parts of clozapine and 80.5-98 parts of Chinese medicinal extract.
The technical scheme has the advantages that: clozapine is used to inhibit various subclasses of borderline personality disorder based on a rational pharmacological response, the primary mechanism of which involves the inhibition of 5-hydroxytryptamine (5-HT) in the brain2A) Receptor and polypeptideDopamine (DA)1) Blocking of the receptor. The traditional Chinese medicine composition matched with clozapine can contain radix curcumae suitable for being taken in all seasons and used for activating blood and relieving pain, promoting qi circulation and resolving depression, clearing heart and cooling blood, benefiting gallbladder and removing jaundice, agilawood used for promoting qi circulation and relieving pain, warming middle-jiao and preventing vomiting, absorbing qi and relieving asthma, and sinomenine used for calming and relieving pain, and meanwhile, a first traditional Chinese medicine extract suitable for spring is arranged based on the difference of the running gravity centers of the five internal organs of the body in four seasons, the first traditional Chinese medicine extract contains radix curcumae and agilawood, and also contains lily and salvia miltiorrhiza suitable for spring, wherein the lily is used for dryness-cough, overstrain and blood-cough, dysphoria and pavor, insomnia and dreaminess, and absentmindedness; saviae Miltiorrhizae radix can be used for treating thoracic obstruction, heart pain, abdominal pain, hypochondriac pain, abdominal mass, pain due to pyretic arthralgia, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease with swelling and pain. The second traditional Chinese medicine extract is suitable for summer, and comprises radix Curcumae, lignum Aquilariae Resinatum, and radix Ophiopogonis, flos Rosae Multiflorae and flos Chrysanthemi suitable for summer, wherein the radix Ophiopogonis is used for treating lung dryness, dry cough, lung carbuncle, yin deficiency, consumptive cough, body fluid injury, thirst, vexation, insomnia, throat pain, intestinal dryness, constipation, blood heat, hematemesis, and epistaxis; flos Rosae Multiflorae can be used for treating summer heat, hematemesis, thirst, dysentery, malaria, and hemorrhage due to knife wound; chrysanthemum can be used for treating wind-heat type common cold, headache, vertigo, conjunctival congestion, swelling and pain, blurred vision, sore, carbuncle, and toxic swelling. The third Chinese medicinal extract is suitable for autumn, and comprises radix Curcumae, lignum Aquilariae Resinatum, radix astragali and rhizoma Gastrodiae suitable for autumn, wherein radix astragali is used for invigorating qi, consolidating superficial resistance, removing toxic substance, expelling pus, promoting urination, and promoting granulation. Can be used for treating deficiency of vital energy, asthenia, chronic diarrhea, proctoptosis, spontaneous perspiration, edema, uterine prolapse, albuminuria due to chronic nephritis, diabetes, and unhealed sore; gastrodia elata is used for calming endogenous wind and relieving spasm, calming liver-yang, dispelling wind and dredging collaterals. The fourth traditional Chinese medicine extract is suitable for winter, and comprises radix Curcumae, lignum Aquilariae Resinatum, radix Ginseng and radix et rhizoma Rhei suitable for winter, wherein radix Ginseng is used for invigorating qi, promoting fluid production, quenching thirst, and treating cough, hematemesis, thirst, stomach deficiency and vomiting; radix et rhizoma Rhei can be used for purging heat toxin, resolving food stagnation, removing blood stasis, treating constipation due to excessive heat, delirium, food stagnation, abdominal distention, dysentery, tenesmus, blood stasis, amenorrhea, abdominal mass, epidemic heat disease, acute ophthalmalgia, hematemesis, epistaxis, yang jaundice, edema, stranguria with turbid urine, carbuncle and ulcer, furuncle, decoction and fire injury, purging heat, dredging intestine, cooling blood, removing toxic substance, removing blood stasis, removing toxic substanceInducing menstruation, and can be used for treating constipation due to excess heat, abdominal pain due to stagnation, dysentery, and jaundice due to damp-heat. The balance of yin and yang of the human body under different solar terms is adjusted, so that side effects caused by incapability of resisting listlessness due to weak physical physiology, such as vomit, headache and the like, can be relieved without damaging the root.
The action of a drug on the body is a periodic rhythm of hours, known as chronopharmacodynamics. Since biorhythms are associated with diseases, many diseases have significant periodic rhythm changes in onset, symptom relief or exacerbation, and the action of drugs also has periodic rhythms, and the concentration and sensitivity of many drugs at target sites may also exhibit circadian rhythm differences, thereby causing differences in temporal pharmacodynamics, including drug dose-responsive circadian rhythms; drug dose-circadian rhythm of blood drug concentration; the concentration of the drug-the circadian rhythm of the response, etc., as well as the chronopharmacology of the drug release system, should be considered in formulating the regimen to achieve safety and efficacy of the drug. At present, the medicine taking in the hour in the theory of traditional Chinese medicine is researched and discovered through modern technical means and is considered when a medicine taking scheme is prepared. The human body meridians run from son to gallbladder, liver and lung when pharbitis, large intestine when Mao, stomach when Chen, spleen when Si, heart and small intestine when Xin, bladder when Shen, pericardium when Wu and triple energizer when Yi, so it has certain influence on the administration of Chinese medicine, for example, spleen and kidney when Si takes, and ginseng is administered at this time to regulate spleen transportation and transformation function and promote absorption. As for sinomenine, in pharmacokinetic studies, the same dose of sinomenine is given, and the concentration of sinomenine in blood plasma and brain is obviously higher than that of unitary sinomenine when applied at the time of Mao. Correspondingly, when the male is in the fourth place (5 to 7), the large intestine is vigorous. When in mortise, the large intestine creeps and expels toxin and dregs; the lung and large intestine are exterior-interior. The lung distributes sufficient fresh blood throughout the whole body, and then promotes the large intestine to enter an excited state, so that the processes of absorbing water and nutrition in food and discharging dregs are completed, and therefore, the sinomenine for metabolism and sedation can reach the maximization of the drug peak value of the human body in the mortise and tenon joint. Based on the above, the Chinese medicinal extract can be taken at Mao, Shi, or on the past, or at the node between the two.
According to a preferred embodiment, clozapine and the extract of Chinese medicine can be taken orally, wherein the extract of Chinese medicine is taken earlier than clozapine. The traditional Chinese medicine extract and clozapine can be respectively placed in different compartments in the storage process so as to ensure the purity and correct administration of the medicine.
The technical scheme has the advantages that: the clozapine and the traditional Chinese medicine extract are not easily affected by factors such as external pH value during digestion and absorption, but are used for smoothing nerve reflection in the body and avoiding abnormality and disorder of information transmission paths such as hormone and the like based on the traditional Chinese medicine extract, and the clozapine can enter the body better than the clozapine, so that the human body preferentially relaxes nerves based on absorbing the components of the traditional Chinese medicine composition and does not resist intertissue nerves when the clozapine enters the human body for action. The Chinese medicinal extract is viscous and can be molded, and is daily wrapped in pill form with medicinal paper, and the medicinal paper is torn off during administration. Because the traditional Chinese medicine extract and the clozapine tablet have obvious differences in hardness, shape and storage mode. When the traditional Chinese medicine extract and clozapine are placed in the same space, the traditional Chinese medicine extract can affect clozapine tablets based on factors such as smell, and on the contrary, the high hardness of the clozapine tablets can generate impact on soft traditional Chinese medicine extract, so that the traditional Chinese medicine extract is deformed and even breaks away from the medicine paper, and bidirectional pollution is caused.
According to a preferred embodiment, the storage device for storing the drug comprises a central small drug box and expanding small drug boxes, wherein the expanding small drug boxes can form an expanding storage space of the central small drug box based on connectors arranged on the four walls of the central small drug box.
The technical scheme has the advantages that: patients suffering from mental diseases, particularly borderline personality disorder, need to take medicine autonomously following the medical advice during home care or hospital care, the medicine categories can comprise at least two categories, and particularly, the pharmaceutical composition for the borderline personality disorder in the invention relates to different oral orders at the same time, and has the obstacle for patients to take medicine. The present invention relates to a storage device for storing a pharmaceutical composition for the treatment of borderline personality disorder as referred to in the present invention. The device can be provided with clozapine independent storage space and independent storage space corresponding to four kinds of traditional Chinese medicine extractum. The patient can get the medicine according to the order of getting it filled respectively to realize the normal action training of marginal personality disorder patient based on the device to the action control of patient's the process of taking medicine, with the data of the process of taking medicine based on the main doctor judgement patient's state of an illness.
According to a preferred embodiment, the medicament is stored by using the medicament storage device described in claim 9 according to any one of claims 1 to 8, so that the medicament is effectively stored and the cross contamination between the medicaments is avoided.
Drawings
FIG. 1 is a flow chart of one embodiment of the present invention;
FIG. 2 is a block diagram of one embodiment of the present invention;
fig. 3 is a schematic structural diagram of the present invention.
List of reference numerals
100: a central pill case; 200: expanding the small medicine boxes; 300: a third party connection unit; 310: a central position; 320: and (5) expanding the positions.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
With the object of stable treatment of borderline personality disorder, the present invention relates to a pharmaceutical composition for the treatment of borderline personality disorder comprising: clozapine tablet 0.5g, cerebroprotein hydrolysate 0.06g (representative of nootropic drugs or brain metabolism promoting drugs) and Chinese medicinal extract 82 g. The first Chinese medicinal extract taken in spring comprises 31.5g of radix Curcumae, 12.6g of lignum Aquilariae Resinatum, 6.3g of Bulbus Lilii and 31.5g of Saviae Miltiorrhizae radix. The second traditional Chinese medicine extract taken in summer comprises 12.8g of radix curcumae, 5.2g of agilawood, 38.4g of radix ophiopogonis, 12.8g of rose and 12.8g of chrysanthemum. The third traditional Chinese medicine extract taken in autumn comprises 5.7g of radix curcumae, 2.3g of agilawood, 62.6g of radix astragali and 11.4g of rhizoma gastrodiae. The fourth traditional Chinese medicine extract taken in winter comprises 18.6g of radix curcumae, 7.5g of agilawood, 18.6g of ginseng and 37.3g of rhubarb. The first Chinese medicinal extract, the second Chinese medicinal extract, the third Chinese medicinal extract and the fourth Chinese medicinal extract are selectively taken according to four seasons by taking spring, summer, autumn and winter as time limits. The extract exists in the form of pill, and is coated with medicinal paper.
Example 2
Fig. 1 shows a flowchart of an embodiment of the intelligent medicine box of the present invention. After the hospital receives the patient with abnormal behavior and distributes the patient with abnormal behavior to the psychiatric/neurologic medical care personnel, the medical care personnel can diagnose the condition of the patient. Under the condition that the patient keeps the clinical manifestations of anxiety, fantasy and/or mania, the medical personnel with the data reading and writing equipment judges the cognitive disorder of the patient through the data reading and writing equipment so as to diagnose the illness state of the patient as an intelligent medicine box user; medical staff configures the intelligent medicine box of the patient (which can comprise medicine distribution and medicine taking information) according to the diagnosis result analyzed and determined by the data reading and writing equipment; when a patient takes medicine by using the intelligent medicine box, the intelligent medicine box generates verification information related to medicine taking information by collecting operation behaviors of the patient on the intelligent medicine box and temporarily storing the operation behaviors in the intelligent medicine box according to a time-related mode. For example, the verification information generated by the smart pill box may be generated based on patient medication behavior data obtained by monitoring patient medication behavior, which may be read by a data reading device at the doctor's site so that the doctor may obtain the patient medication behavior data and the verification information related to the medication administration information. After obtaining the medicine taking behavior data of the patient and the verification information related to the medicine taking information, the doctor can know the current mental state of the patient by combining the current clinical manifestation of the patient for the double-time clinical consultation and the secondary mental evaluation result, thereby judging the progress degree of the patient's condition.
According to a preferred embodiment, in the event that the patient is diagnosed with mood-unstable personality disorder, the healthcare worker configures the smart medication box with configuration information comprising: expected behavior of the patient, and medication intake information. The medication intake information can be used to trigger the playing of a prompt voice or instruction by the intelligent medication box for the purpose of guiding the patient to take clozapine and the traditional Chinese medicine extract correctly. The expected action of patient carries out data set for the action that medical personnel probably demonstrate in advance to current patient according to past patient action data, and when the patient used intelligent medicine box or took the action, intelligence medicine box monitoring patient action data triggered the alarm instruction with predetermineeing when data reach certain coincidence, and the instruction can be sent to guardian terminal to carry the patient to make a double-pass through guardian terminal suggestion.
When the patient's condition worsens, the patient who holds patient monitoring unit carries out abnormal operation to the intelligent medicine box that is used for monitoring patient operation intelligence medicine box. The intelligent medicine box collects data for at least one time of abnormal operation in sensing modes such as pressure change, speed change and image shooting, carries out data matching on collected data and abnormal behavior data preset by medical personnel, and judges the aggravation of the patient by the intelligent medicine box when reaching a preset abnormal behavior data threshold value. When the state of an illness of the patient alleviates, the data of normal medicine taking operation of the patient who holds the patient monitoring unit at least once can be gathered to the intelligence medicine box in perception modes such as pressure change, speed change, image shooting, and the state of an illness of the patient is judged to alleviate by the intelligence medicine box when judging modes such as behavior data correct rate or correct medicine taking times in the operation process accord with the preset conditions of the intelligent medicine box by medical personnel. The intelligent medicine box triggers an instruction of sending a re-diagnosis prompt to a guardian terminal held by the guardian based on the judgment result of the patient disease condition reduction or aggravation.
According to a preferred embodiment, in the process of the return visit, medical staff with data reading equipment reads data of the intelligent medicine box and the patient monitoring unit, communicates with a guardian to obtain information feedback of the patient on the non-behavioral diseases, and performs disease diagnosis by combining the results of physiological examination, consciousness level or cognition metric table of the patient. Medical care personnel gather statistics according to the data and export the behavior data so as to judge the state of an illness of the patient. And the intelligent medicine box is subjected to medicine distribution and medicine taking information alternation again based on the judgment of the disease progress.
According to a preferred embodiment, after the medical staff distributes and stores the medicine to the intelligent medicine box and finishes the medicine taking setting, the intelligent medicine box receives the medicine taking prompt instruction and simultaneously sends a medicine taking prompt to the terminals of the patient monitoring unit and the guardian which are worn on the wrist or other close-to-the-skin positions of the patient, the patient holding the patient monitoring unit responds to the issued prompt to be close to the intelligent medicine box in a certain range or touch the intelligent medicine box, the intelligent medicine box selectively opens a sealing cover of a space containing the medicine to be taken based on the received signal sent by the patient monitoring unit, the patient is allowed to take the correct medicine under the forward guidance of the intelligent medicine box, the intelligent medicine box monitors the behavior of the patient in real time based on the monitoring and the self pressure of the patient monitoring unit held by the patient, and the monitoring of the weight change is stored in an intelligent medicine box storage area in a data form.
According to a preferred embodiment, the patient's medication intake can be monitored by the smart cartridge in the form of a captured image. In particular, upon ingestion of the first composition by a patient, the first composition can be provided in a pharmaceutical pack and administered by mixing with water, as opposed to direct and water ingestion of the second composition. Two significantly different modes of administration can be based on the intelligent kit comparing the ingestion of the first composition by the patient of a critical motion and the ingestion of the second composition by the patient of a critical motion, e.g., the first composition exists as a decocted liquid and can be swallowed directly by the patient in liquid form, the intelligent kit identifies the ingestion of the first composition by image ingestion of the liquid form of the first composition or by the patient's direct swallowing without water ingestion; the second composition mostly exists in a tablet state, and when a patient takes the second composition, the intelligent medicine box can recognize the circular shape of the second composition through image taking or the action of taking the water from the patient and mixing the medicine for taking.
According to a preferred embodiment, the terminal of the guardian responds to the issued prompt and receives monitoring data of the medicine taking behavior of the patient through the terminal, wherein the monitoring data comprises medicine taking types, medicine taking weights and/or sealing cover states; if the patient does not interact with the intelligent medicine box under the prompt within a certain time, the intelligent medicine box sends early warning to the guardian terminal.
According to a preferred embodiment, the medical staff reads the data and information of the intelligent medicine box storage area through the data reading device when the patient goes for a doctor, and the data and information are used for judging the illness state degree of the patient.
Specifically, under the condition that the patient is diagnosed with unstable mood personality disorder, the medical staff places clozapine in the central small medicine box 100, distinguishes the small expanded medicine boxes 200 in each row according to the four seasons, and places a type of traditional Chinese medicine extract for taking in one season in each small expanded medicine box 200 corresponding to one outer wall of the central small medicine box 100. The patient monitoring unit, the guardian terminal and the intelligent medicine box which are held by the patient form data connection through a mobile communication network and/or WiFi. At the noon of the first day, the instruction is triggered to the settlement procedure in the intelligence medicine box, and the intelligence medicine box sends the oral suggestion of traditional chinese medicine to the guardian terminal that the patient monitoring unit that the patient held and the guardian held binding, and the suggestion that the patient received patient monitoring unit is attracted attention to based on the pronunciation guide operation intelligence medicine box of intelligence medicine box, take and be used for when the traditional chinese medicine extract that the day was taken with the hour. After the traditional Chinese medicine extract is taken correctly, the intelligent medicine box detects the behavior and the self change of the patient. Based on the dual judgment of the change of the intelligent medicine box and the correct medicine taking operation of the patient, the intelligent medicine box sends the information that the traditional Chinese medicine extract is taken to the guardian terminal bound by the guardian, and guides the patient to take medicine next. The intelligent medicine box for taking the medicine entering the next stage selects positive guidance or negative interference or patient medicine taking prompts contained in both through the patient taking state of the traditional Chinese medicine extract in the last stage, such as informing the patient of the medicine taking position and quantity in the next stage, playing interference music and recording the medicine taking behaviors of the patient. And after the patient finishes the administration of the clozapine in the second stage, sending an administration completion notification to a guardian terminal bound by the guardian. The intelligent medicine box can be kept away from the intelligent medicine box to a certain distance to the patient monitoring unit held by the patient continuously.
According to a preferred embodiment, the patient monitoring unit can be a bracelet, necklace or monitoring device co-located with the patient in one space. The patient monitoring unit can draw the attention of the patient through voice, vibration or light and the like, so that the next medicine taking guide is carried out. Preferably, because the living space of the patient with the mood-unstable personality disorder is fixed in the nursing process, the patient monitoring unit can be a camera shooting assembly with a prompt function, image shooting is carried out on behaviors of the patient before taking medicine and after taking medicine at the middle level in the medicine taking process, and image data for judging whether the behaviors are abnormal or normal is provided for the intelligent medicine box.
Example 3
The invention relates to a medicine storage system, which comprises a central small medicine box 100 and expanded small medicine boxes 200, wherein the expanded small medicine boxes 200 can form expanded storage spaces of the central small medicine box 100 based on connectors arranged on four walls of the central small medicine box 100, and the expanded storage spaces are shown in fig. 3. The central pill box 100 is used to store clozapine. The small developed medicine box 200 is used for storing traditional Chinese medicine extract. The expansion tablets 200 can be connected to the center tablet 100 through the third party connection unit 300. Preferably, the third party connection unit 300 can be an electromagnetic connector. The walls of the central small medicine box 100 are respectively provided with a main connector, and one side of the opposite sides of the expanded small medicine box 200 is provided with an auxiliary connector, and one side is provided with a main connector, wherein the main connector and the auxiliary connector can be mutually adsorbed in the electrified state of the central small medicine box 100 and the expanded small medicine box 200. The expanded small medicine boxes 200 are respectively arranged on the four walls of the central small medicine box 100 based on the classification of the first traditional Chinese medicine extract, the second traditional Chinese medicine extract, the third traditional Chinese medicine extract and the fourth traditional Chinese medicine extract. As shown in fig. 3, the center pill case 100 can be extended in a direction in which the small pill cases 200 are connected based on the adsorption of the small pill cases 200 to each other or the center pill case 100, forming a cross-shaped pill case. This medicine system of depositing can also be named intelligent medicine box.
According to a preferred embodiment, the third party connection unit 300 can also be a containing box with a snap or suction connection at the bottom, as shown in fig. 2, provided with at least one central location 310 and at least one expansion location 320. The central position 310 is used for fixing the small medicine box 100 and realizing the signal connection between the small medicine box 100 and the third party connecting unit 300. The extension station 320 is used for fixing the extension small medicine box 200 and realizing signal connection with the third party connecting unit 300, so as to realize signal connection with the central small medicine box 100 through the third party connecting unit 300. The containing box is provided with a cover which can seal the central small medicine box 100 and the expanding small medicine box 200 contained therein. The central small medicine box 100 and the expanded small medicine boxes 200 are also provided with small covers corresponding to the spaces of the individual medicine boxes thereof, respectively. The small cover can be automatically opened or closed under the control of a signal.
According to a preferred embodiment, the third party connection unit 300 and/or the central pill box 100 is provided with a sound and light source player. The sound player can broadcast a medication intake indication voice, an alarm or other guidance music. The light source player is used for flashing light sources with different colors or frequencies to prompt or guide medicine taking.
According to a preferred embodiment, the medicine box is provided with a GPS positioning system capable of precisely controlling time based on the longitude and latitude of the current patient and performing hour conversion based on the current time, thereby performing the administration of the traditional Chinese medicine at precise times and hours.
According to a preferred embodiment, the central pill box 100 is provided with a control center. The control center is used for receiving signals, sending instructions and carrying out logic judgment. The control center is arranged with the order of opening the lids based on the individual lid placement of the compartments. Based on abnormal emotions and behaviors such as mania, anxiety or absentmindedness possibly existing in patients with borderline personality disorder or other mental diseases, if the medicine storage device has no control measures, the patients are very likely to take other medicines by mistake or mistake the medicine taking sequence when taking medicines alone. The invention is provided with at least five medicines comprising clozapine, a first traditional Chinese medicine extract, a second traditional Chinese medicine extract, a third traditional Chinese medicine extract and a fourth traditional Chinese medicine extract. Clozapine is placed in the central pill box 100. The first traditional Chinese medicine extract, the second traditional Chinese medicine extract, the third traditional Chinese medicine extract and the fourth traditional Chinese medicine extract are respectively placed in different small expanding medicine boxes 200. Preferably, the small expanded medicine boxes 200 containing the first, second, third and fourth traditional Chinese medicine extracts are respectively placed in four directions of the small central medicine box 100, so that the medicine boxes form a linear cross shape. Based on the fact that the central small medicine box 100 and the expansion small medicine boxes 200 are connected with the third-party connecting unit 300, the central small medicine box 100 and the expansion small medicine boxes 200 form a complete signal transmission path. The control center for guiding the patient to take the medication performs the medication prompting of the pharmaceutical composition based on the following logic:
1) the medical staff or the normal mentality-promoting staff of the family members place clozapine in the central small medicine box 100, the first traditional Chinese medicine extract is placed in the first row of the small medicine boxes 200, and the second traditional Chinese medicine extract is placed in the second row of the small medicine boxes 200. Placing the third Chinese medicinal extract in the third row of the expanded small medicine boxes 200, and placing the fourth Chinese medicinal extract in the fourth row of the expanded small medicine boxes 200;
2) program setting of medicine taking prompt is performed through a terminal or a display arranged on the third party connecting unit 300 and/or the central medicine box 100;
3) at the set time and season, the third party connecting unit 300 and/or the central medicine box 100 sends out voice or alarm to attract the attention of the patient, and the voice is switched when the whole induction medicine box is taken (speed induction or other induction modes) to guide the patient to take the traditional Chinese medicine extract;
4) the voice content can contain the position of the expanded small medicine box 200 where the traditional Chinese medicine extract to be taken is located, the number of the taken granules and other contents, at the moment, the small sealing cover of an independent compartment containing the medicine to be taken in the expanded small medicine box 200 can be opened, the small sealing covers of other positions are all in a state that the small sealing covers cannot be opened, and the device can sense the specific position of the small sealing cover which is tried to be opened by a patient and store data until the small sealing cover of the compartment containing the medicine to be taken in the expanded small medicine box 200 is opened;
5) the patient takes the medicine, the weight of the medicine in the compartment changes, so that the control system is activated to send a next voice-guided playing instruction, and meanwhile, the independent small sealing cover of the central small medicine box 100 can be opened;
6) the patient opens the small sealing cover of the small medicine box 100 at the center based on the voice prompt to take the medicine, the control center records the behavior data of the patient for taking the medicine after the small sealing cover is opened, and sends an instruction to make a sound report to prompt the patient to close the sealing cover arranged on the third-party connecting unit 300;
7) the whole process is completed without errors, the control center sends an instruction to play a completion instruction and plays voice or music and the like to improve the achievement feeling of the patient;
8) the control center can store the action process of taking medicine of the patient within a certain time period, the content can comprise the position and time of uncapping selection and the weight of medicine selection, and the data content is allowed to be copied or transferred to other storage terminals.
According to a preferred embodiment, when the combined drug clozapine and traditional Chinese medicine extract are placed in a cartridge, the underlying logic or most basic logic of the cartridge is that at a set time and order, the small lid of one or more extended cartridges containing the traditional Chinese medicine extract is opened first and only, while the other lids are closed and cannot be opened. The logic judgment of the medicine taking of the patient is carried out through the behavior of the patient and/or the gravity change in the expanded small medicine box 200, and the small central medicine box 100 containing clozapine can be automatically opened after the opened expanded medicine box is pressed and closed, so that at least the first traditional Chinese medicine extract/the second traditional Chinese medicine extract/the third traditional Chinese medicine extract/the fourth traditional Chinese medicine extract are preferentially taken, and the clozapine cannot be taken by the patient.
One of the advantages of the device is the controllability of the medicine taking process of the patient. The basic features of borderline personality disorder are instability and marked impulsivity of interpersonal relationships, self-image and emotions. Because of unstable characters and violent impulsive emotion, uncontrollable and multiple medicines are easily taken by mistake in the medicine taking process. Based on the control center to the control of opening and shutting of the little closing cap of different little medicine boxes to guide the patient of taking medicine to carry out the medicine oral according to suggestion such as pronunciation, light. The device is an intelligent medicine box, and the control center can receive the medicine from a gravity sensor, a pressure sensor, a voice player and the like. Based on the change of the gravity of the medicine, the opening and closing of the small sealing cover and the connection condition between the small medicine boxes, the control center can record and analyze the change of data, so that the next step of judgment of instructions is carried out.
The second advantage of this device can monitor patient's action normal degree through the operation of taking medicine, and the action that the patient was carrying out the medicine according to the guide and is taking and taking the in-process promptly can form certain interaction with the device to make the device can collect patient's action data. In the interaction process, the device can reduce or increase the medicine taking difficulty of the user by giving positive feedback such as voice, music and the like or negative feedback such as information interference and the like to the user. The information interference method includes giving error information in the guide information, playing discordant tones or environmental noise, increasing environmental complexity or operation complexity, etc.
A third advantage of the present device is to provide a review time node for the guardian. Because patients with mental diseases are easy to relapse, and emotional accumulation points of the patients are easy to trigger under special scenes or conditions, the mental development of the patients is positive or negative, and the mental development cannot be clearly known by guardians. The medicine taking behavior is a stable and continuous behavior node, and the disease progress analysis of the patient can be carried out through behavior judgment under the condition of not stimulating the patient. The intelligent medicine box can judge the forward or backward development of the current mental state of the patient based on the information collection of the medicine taking behaviors of the patient and the matching of normal behavior data of past data experience of medical staff. Further, when the threshold set by the medical staff is triggered in the process of mental development, the intelligent medicine box sends a re-diagnosis prompt to the guardian terminal bound by the guardian, so that the patient can be ensured to be correctly treated at the correct time node, and the situation that the mental deterioration of the patient is not found to cause disease deterioration or the mental development of the patient is prevented, but the patient still takes excessive medicines to cause reverse emotion is prevented.
According to a preferred embodiment, the first row of expanded pill boxes 200 can correspond to a green light. The second column of developed pill boxes 200 can correspond to a red light. The third column of expanded pill boxes 200 can correspond to a yellow light. The fourth column of expanded pill boxes 200 can correspond to a milky light. The patient is reminded of the four seasons through different colors, and the forward guiding information of judgment is increased. Further, under the forward guiding effect of light, the voice prompt can be an error information prompt so as to increase the complexity of information processing, and is used for increasing the medicine taking difficulty of the patient when the illness state of the patient is further stabilized.
Further, the device can record the behaviors of mental patients such as negative medicine taking of borderline personality disorder and the like and record the behaviors into a database. The physician can interpret the health outcome by the behavioral record data in combination with the individual's physiological indications to form a digital biomarker to provide the physician with ancillary assistance in subsequent rehabilitation of the patient.
It should be noted that the above-mentioned embodiments are exemplary, and that those skilled in the art, having benefit of the present disclosure, may devise various arrangements that are within the scope of the present disclosure and that fall within the scope of the invention. It should be understood by those skilled in the art that the present specification and figures are illustrative only and are not limiting upon the claims. The scope of the invention is defined by the claims and their equivalents.
Claims (10)
1. A medication storage system comprising a medication for treating borderline personality disorder and a storage device for storing the medication, wherein the medication for treating borderline personality disorder consists of two compositions: the time constitutes the first composition of the critical condition for taking and the dosage constitutes the second composition of the critical condition for taking.
2. A medication storage system according to claim 1, wherein prescribed doses of said second composition are provided by said medication storage system in a time-dependent manner, and said medication storage system stores and processes administration information in an image acquisition manner in relation to the time of provision of the second composition.
3. A medication storage system according to claim 1 or 2, wherein said first composition comprises at least four compositions having times constituting key taking conditions and respective times of taking being different from each other, wherein a prescribed time of taking of respective ones of said first compositions is specified by said medication storage system in a manner correlated to a time of provision of the first composition.
4. A medication storage system according to any of the preceding claims, wherein said medication storage system is image capturing for storing and processing administration information relating to the time of delivery of the second composition for respective ones of said first compositions.
5. The medicine storage system according to any one of the preceding claims, wherein the first and second compositions of the medicine constituting the borderline personality disorder are stored in the medicine storage system without intersecting each other, wherein the medicine storage system stores information relating to the timing of taking of at least the "first composition whose time constitutes a key taking condition" and the "second composition whose dose constitutes a key taking condition" in an image acquisition manner, so that the timing of taking of the first and second compositions stored without intersecting each other is stored in relation to the taking behavior and can be subjected to the time-correlation analysis.
6. The drug storage system of any of the preceding claims wherein the first composition of the drugs constituting the borderline personality disorder is preferentially administered in an order-dependent manner specified by the drug storage system.
7. A drug storage system according to any of the preceding claims, wherein the first and second compositions of the drug constituting the borderline personality disorder are administered by ingestion into the digestive system.
8. A drug storage system according to any of the preceding claims, wherein one of the four components of the first composition constituting the medicament of borderline personality disorder may be provided in the form of a slow release layer outside the second composition.
9. A drug storage system according to any of the preceding claims, wherein the drug storage system takes the first and second compositions sequentially in time by alerting the patient and/or their care giver to take the respective patients for the purpose of enhancing the drug effects of each other.
10. A method for storing a drug, characterized by storing or taking a pharmaceutical composition as described in claims 1 to 8 by using the drug storage system described in claims 1 to 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110986251.1A CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110986251.1A CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113662857A true CN113662857A (en) | 2021-11-19 |
CN113662857B CN113662857B (en) | 2024-04-05 |
Family
ID=78546614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110986251.1A Active CN113662857B (en) | 2021-08-25 | 2021-08-25 | Drug storage system and method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113662857B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113662858A (en) * | 2021-08-25 | 2021-11-19 | 首都医科大学宣武医院 | Intelligent medicine taking prompting system and method |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084828A (en) * | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
US20100060435A1 (en) * | 2008-09-10 | 2010-03-11 | Sun Lee Bang | Apparatus for supporting a medicine-taking service and method for supporting a medicine-taking service using the same |
CN201642854U (en) * | 2010-02-04 | 2010-11-24 | 何伊仁 | Electronic medicine box |
CN105662850A (en) * | 2016-01-11 | 2016-06-15 | 上海云樱医疗科技有限公司 | Intelligent medicine box equipment and medicine taking management method |
CN205672239U (en) * | 2016-03-07 | 2016-11-09 | 坦通自动化(上海)有限公司 | A kind of family expenses drug control device and intelligence control system thereof |
CN106420347A (en) * | 2016-11-15 | 2017-02-22 | 新疆医科大学第附属医院 | Method for improving medication compliance of patient and intelligent medicine box system |
CN106580708A (en) * | 2015-10-19 | 2017-04-26 | 北京超思电子技术有限责任公司 | Medicine taking prompting device and medicine taking prompting system |
CN107308003A (en) * | 2017-06-07 | 2017-11-03 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box for carrying User logs in interface |
CN107890422A (en) * | 2017-10-16 | 2018-04-10 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box of supervision and management chronic medication |
US20180280245A1 (en) * | 2013-10-23 | 2018-10-04 | Nexpil, Inc. | Medication Compliance Alert Device |
CN108743371A (en) * | 2018-06-01 | 2018-11-06 | 武汉大学人民医院(湖北省人民医院) | One kind can share intelligent medicine box system and its application process |
CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
-
2021
- 2021-08-25 CN CN202110986251.1A patent/CN113662857B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084828A (en) * | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
US20100060435A1 (en) * | 2008-09-10 | 2010-03-11 | Sun Lee Bang | Apparatus for supporting a medicine-taking service and method for supporting a medicine-taking service using the same |
CN201642854U (en) * | 2010-02-04 | 2010-11-24 | 何伊仁 | Electronic medicine box |
US20180280245A1 (en) * | 2013-10-23 | 2018-10-04 | Nexpil, Inc. | Medication Compliance Alert Device |
CN106580708A (en) * | 2015-10-19 | 2017-04-26 | 北京超思电子技术有限责任公司 | Medicine taking prompting device and medicine taking prompting system |
CN105662850A (en) * | 2016-01-11 | 2016-06-15 | 上海云樱医疗科技有限公司 | Intelligent medicine box equipment and medicine taking management method |
CN205672239U (en) * | 2016-03-07 | 2016-11-09 | 坦通自动化(上海)有限公司 | A kind of family expenses drug control device and intelligence control system thereof |
CN106420347A (en) * | 2016-11-15 | 2017-02-22 | 新疆医科大学第附属医院 | Method for improving medication compliance of patient and intelligent medicine box system |
CN107308003A (en) * | 2017-06-07 | 2017-11-03 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box for carrying User logs in interface |
CN107890422A (en) * | 2017-10-16 | 2018-04-10 | 深圳市南山区慢性病防治院 | A kind of novel intelligent medicine box of supervision and management chronic medication |
CN108743371A (en) * | 2018-06-01 | 2018-11-06 | 武汉大学人民医院(湖北省人民医院) | One kind can share intelligent medicine box system and its application process |
CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113662858A (en) * | 2021-08-25 | 2021-11-19 | 首都医科大学宣武医院 | Intelligent medicine taking prompting system and method |
CN113662858B (en) * | 2021-08-25 | 2024-03-29 | 首都医科大学宣武医院 | Intelligent medicine taking prompt system and method |
Also Published As
Publication number | Publication date |
---|---|
CN113662857B (en) | 2024-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110504010A (en) | Intelligent diagnosis and treatment management method, system and the intelligent clinic using it | |
JP2017500991A (en) | Life maintenance mode, brain suppression and personal health information platform | |
CN101926950B (en) | Brain-invigorating traditional Chinese medicine composite and preparation method and detection method thereof | |
CN112216364A (en) | Medication prescription pushing method and system based on artificial intelligence | |
CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
CN113662857B (en) | Drug storage system and method | |
CN103536757B (en) | Traditional Chinese medicine composition having effects of tonifying kidney, replenishing essence, tonifying qi, nourishing blood and consolidating basis, and preparation method and application thereof | |
CN104474451B (en) | Rush down peace ball | |
CN111658735A (en) | Intelligent system plaster for conditioning physique and preventing and treating various gastrointestinal diseases and preparation method | |
AU2021104559A4 (en) | Personal health management system based on image recognition and big data | |
CN108578667A (en) | A kind of drug that treating methamphetamine abstinence syndrome and its application | |
CN104368073A (en) | Sleep conditioning method | |
CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
CN103169847A (en) | Traditional Chinese medicine extraction pill for treating deficiency of kidney-essence and impotence and premature ejaculation and preparation method thereof | |
CN113707267A (en) | Method and system for intelligently recommending administration route | |
Nowak | The effect of timed blue-green light on sleep-wake patterns in women with Alzheimer's disease | |
CN115779031B (en) | Traditional Chinese medicine composition for treating insomnia | |
CN101670027A (en) | Compound fleece-flower root oral liquid, preparation method thereof and quality control method | |
CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
CN107375600A (en) | A kind of Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease and its application | |
CN115998793B (en) | Vigour-preserving soup for improving learning and memory capacity of organism and preparation method thereof | |
CN107260851A (en) | A kind of Chinese medicine composition for treating weakness constipation | |
Kumar | Elucidation of the factors to be considered in ayurvedic clinical | |
CN106729154A (en) | A kind of Chinese medicine for treating spleen-deficient non-inflammatory vaginal discharge diseases and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |